SpotitEarly, an Israeli medtech startup that specializes in the treatment of cancer, raised $6.2 million in a Seed funding round led by Hanaco Ventures. The company uses artificial intelligence (AI) to copy the smelling abilities of dogs in its tech, believe it or not.
Founded in 2020 by four friends with experience in technology, digital health algorithmics, product development, and entrepreneurship – Roi Ophir, Ohad Sharon, Udi Bobrovsky, and CEO Ariel Ben Dayan, SpotitEarly develops scent based multi-cancer early detection screening test, combining bio detectors taken from dogs’ olfactory capabilities together with proprietary AI stack.
Everyone knows that dogs have a great sense of smell. Police use them to detect illegal drugs and even explosives. They are also used in rescue operations to find people buried under piles of rubble. And now SpotitEarly has found a way to recreate a dog’s smelling ability using AI and somehow it can detect cancer. But how?
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
Well, believe it or not, cancers actually have their own scent. And that scent can be detected in a person’s breath. As of today, the SpotitEarly tech can detect lung, prostate, breast, and colon cancer, but the company says it will be able to apply it to more cancers in the near future.
That an Israeli company has developed this amazing new technology should not surprise anyone who has followed the daily news coming out of Israel Startup Nation. Israeli firms are at the forefront of new medical technologies and Israeli researchers seem to come up with new medical treatments on almost a daily basis. And Israelis have been leaders in the world in developing new cancer treatments and early detection tech.
In April, researchers from Tel Aviv University developed yet another new treatment for cancer. They proved that a drug delivery system based on lipid nanoparticles can utilize RNA to overcome resistance to both chemotherapy and immunotherapy in cancer treatments. They declared that the study opens a new path to a personalized and precisely targeted battle against cancer.
“The statistics speak for themselves,” Ben Dayan explained. “Nine out of 10 cancer patients who discover the disease early will survive. In contrast, unfortunately, nine out of 10 who discover it late will not survive. The ability to combine technology with a canine’s developed sense of smell, to create an accessible and accurate test that covers many different cancers, will significantly increase the number of people who get tested regularly. It will contribute to the saving of many lives.”